Active Filter(s):
Details:
OxaliTEX, is the first clinical candidate developed from the TEX Core platform for the treatment of platinum-resistant ovarian cancer, has received a notice of allowance for patent in Korea adds further global protection.
Lead Product(s): Oxaliplatin,Texaphryn
Therapeutic Area: Oncology Product Name: OxaliTEX
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 30, 2022
Details:
OxaliTEX is first clinical candidate developed from TEX Core platform for treatment of ovarian cancer, also overcomes platinum resistance, and is tumor localizing, well-tolerated, and MRI-detectable to allow clinicians and patients to easily monitor tumor regression.
Lead Product(s): Oxaliplatin Pt(IV) Prodrug,Texaphyrin
Therapeutic Area: Oncology Product Name: OxaliTEX
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2022